| Code | CSB-RA888016MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Recibokibart, targeting IL1RL2 (Interleukin 1 Receptor Like 2), also known as IL-36R. IL1RL2 functions as a receptor for IL-36 cytokines, playing a critical role in innate immune responses and inflammatory signaling pathways. Upon ligand binding, IL1RL2 activates downstream NF-κB and MAPK signaling cascades, promoting the production of pro-inflammatory mediators. This receptor is implicated in various inflammatory and autoimmune conditions, including psoriasis, inflammatory bowel disease, and other skin disorders characterized by excessive keratinocyte activation and neutrophil recruitment.
Recibokibart represents a therapeutic antibody designed to block IL-36 receptor signaling, offering potential intervention in IL-36-mediated inflammatory diseases. This biosimilar antibody provides researchers with a valuable tool for investigating IL1RL2 biology, studying IL-36 signaling mechanisms, and exploring therapeutic strategies for inflammatory conditions. It supports studies examining cytokine-receptor interactions, immune cell activation, and disease pathogenesis in relevant experimental models.
There are currently no reviews for this product.